CDC Director Walensky to reorganize agency after admitting Covid pandemic response fell short

CDC Director Walensky to reorganize agency after admitting Covid pandemic response fell short


Rochelle Walensky, MD, MPH, Director, United States Centers for Disease Control and Prevention; speaks during the COVID Federal Response Hearing on Capitol Hill on June 16, 2022 in Washington, DC.

Joe Raedle | Getty Images

CDC Director Rochelle Walensky is reorganizing the agency, saying it didn’t react quickly enough during the Covid pandemic, according an internal review of the agency’s operations released on Wednesday.

Walensky laid out several organizational changes the Centers for Disease Control and Prevention will take over the coming months to correct missteps and failures that occurred during the last 2.5 years of the pandemic, according to a fact sheet.

“For 75 years, CDC and public health have been preparing for COVID-19, and in our big moment, our performance did not reliably meet expectations,” Walensky said in a statement.  ”My goal is a new, public health action-oriented culture at CDC that emphasizes accountability, collaboration, communication, and timeliness.”

The central objectives of the reorganization are focused on sharing scientific data faster and making it easier for the public to understand health guidance, according to the briefing document. Walensky launched the review in April after the massive winter surge of infections from the omicron variant upended the nation’s public health response.

The CDC repeatedly faced criticism during the pandemic for confusing public health recommendations and releasing data too slowly through retrospective reports that were outpaced by the rapid spread of the virus. Public health experts were often frustrated that briefings on the pandemic relied on data from other countries, such as the United Kingdom and Israel.

Walensky is appointing an executive to lead a team that will implement changes. The CDC will also create a new executive council that reports directly to Walensky to determine the agency’s key priorities backed up by budget decisions.

The agency’s science and laboratory sciences divisions, which play crucial roles in investigating and tracking public health threats such as Covid, will also report to the CDC director.

The CDC is also creating an equity office to make sure agency’s workforce reflects the U.S. population and better communicates public health guidance across all groups.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More